Literature DB >> 25362702

Lead time and overdiagnosis.

Stuart G Baker1, Philip C Prorok2, Barnett S Kramer2.   

Abstract

Mesh：

Year:  2014        PMID： 25362702     DOI： 10.1093/jnci/dju346

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.

Authors:  Roman Gulati; Eric J Feuer; Ruth Etzioni
Journal:  Am J Epidemiol       Date:  2016-06-29       Impact factor: 4.897

2.  Editorial: Challenges in Quantifying Overdiagnosis.

Authors:  Stuart G Baker; Philip C Prorok; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

3.  Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status.

Authors:  Ju-Hyun Park; William F Anderson; Mitchell H Gail
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

4.  Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.

Authors:  Marc D Ryser; Jane Lange; Lurdes Y T Inoue; Ellen S O'Meara; Charlotte Gard; Diana L Miglioretti; Jean-Luc Bulliard; Andrew F Brouwer; E Shelley Hwang; Ruth B Etzioni
Journal:  Ann Intern Med       Date:  2022-03-01       Impact factor: 51.598

Review 5.  Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them.

Authors:  Ruth Etzioni; Roman Gulati
Journal:  J Natl Cancer Inst       Date:  2015-11-18       Impact factor: 13.506

6.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.

Authors:  Betsy A Kohler; Recinda L Sherman; Nadia Howlader; Ahmedin Jemal; A Blythe Ryerson; Kevin A Henry; Francis P Boscoe; Kathleen A Cronin; Andrew Lake; Anne-Michelle Noone; S Jane Henley; Christie R Eheman; Robert N Anderson; Lynne Penberthy
Journal:  J Natl Cancer Inst       Date:  2015-03-30       Impact factor: 13.506

7.  Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.

Authors:  Thanya Pathirana; Andrew Hayen; Jenny Doust; Paul Glasziou; Katy Bell
Journal:  BMJ Open       Date:  2019-03-10       Impact factor: 2.692

8.  Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.

Authors:  Gemma Jacklyn; Paul Glasziou; Petra Macaskill; Alexandra Barratt
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.